+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 53 Actively Recruiting clinical trials

C

Actively Recruiting

Researchers are evaluating the efficacy and safety of rilvegostomig compared to pembrolizumab, both combined with platinum-based doublet chemotherapy, as a first-line treatment for patients with locally advanced or metastatic non-squamous non-small cell lung cancer NSCLC whose tumors express PD-L1 at 1% or higher. This Phase III, randomized, double-blind, global study focuses on patients without certain genetic mutations who have advanced disease not suitable for curative treatment. The trial aims to provide new treatment options for this patient group by comparing two immunotherapy approaches combined with chemotherapy. Participants receive either rilvegostomig or pembrolizumab, each given intravenously on Day 1 of every 21-day cycle, alongside platinum-based doublet chemotherapy carboplatin or cisplatin for up to four cycles. After chemotherapy, patients continue with maintenance monotherapy of their assigned immunotherapy rilvegostomig or pembrolizumab plus pemetrexed given intravenously on Day 1 of each 21-day cycle. This treatment continues until disease progression or unacceptable toxicity. Throughout the study, participants undergo regular assessments including tumor measurements by CT or MRI scans, organ and bone marrow function tests, and monitoring for side effects. Researchers will measure overall survival and progression-free survival for up to approximately six years. Patient-reported outcomes on physical functioning, quality of life, and lung cancer symptoms are also collected. Safety and pharmacokinetics of rilvegostomig are monitored to understand treatment effects and tolerability over the long term.

Age: 18Years +All GendersPhase 3
301 locations
G

Actively Recruiting

Researchers are evaluating the safety and effectiveness of rilvegostomig combined with platinum-based chemotherapy compared to pembrolizumab combined with the same chemotherapy for first-line treatment of patients with locally advanced or metastatic squamous non-small cell lung cancer mNSCLC whose tumors express PD-L1. This Phase III, randomized, double-blind study involves participants whose tumors have a PD-L1 expression of 1% or higher. Participants receive either rilvegostomig or pembrolizumab intravenously on Day 1 of each 21-day cycle, combined with carboplatin and paclitaxel or nab-paclitaxel chemotherapy. Chemotherapy is given for up to 4 cycles, with nab-paclitaxel administered on Days 1, 8, and 15 of each cycle. After the chemotherapy cycles, participants continue with the assigned drug alone. Throughout the study, researchers monitor overall survival and progression-free survival for up to approximately six years. Additional assessments include response rates, duration of response, drug levels in the body, immune reactions to rilvegostomig, and patient-reported physical functioning, quality of life, and lung cancer symptoms. Participants undergo regular evaluations to assess these outcomes and safety throughout the study period.

Age: 18Years +All GendersPhase 3
333 locations
N

Actively Recruiting

Researchers are conducting a prospective, multicenter cohort study to follow children with idiopathic nephrotic syndrome INS, a rare kidney disease. The study aims to collect data on pediatric patients treated by pediatric nephrologists in France and its overseas territories to better understand the diseases characteristics and support future clinical trials. The study involves regularly recording medical, biological, psychological, and social data through routine clinical follow-ups, hospitalizations, and consultations. Additionally, annual telephone interviews will be conducted for patients in remission. Quality of life, treatment adherence, and treatment impact questionnaires will also be collected. A biobank is established to collect blood, urine, hair, and nail samples at the disease onset before immunosuppressive treatment begins. Participants will be followed from disease onset until age 18 or transfer to adult nephrology care. Data is collected via a secure website, medically validated and entered by clinical research staff. The main outcome is the number of cases included and their characteristics over two years. Participation involves routine care visits, interviews, and questionnaires, with continued monitoring planned through the study period ending in 2048.

Age: 0 - 18YearsAll Genders
48 locations
S

Actively Recruiting

Researchers are evaluating the safety and effects of a new drug called NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction HFpEF or Heart Failure with mildly reduced Ejection Fraction HFmrEF who also have excess body weight. This study compares NNC0487-0111 against a placebo to determine if it is safe and effective for treating these heart conditions in people with obesity. The study is a randomized, controlled trial conducted by Novo Nordisk AS. Participants will receive either NNC0487-0111 or a placebo by subcutaneous injection once a week. The study drug dose may increase over time for those receiving NNC0487-0111. Treatment assignment is random, and the study includes a parallel design with two groups one receiving the experimental drug and one receiving placebo. The treatment period and monitoring last up to 165 weeks. During the study, participants will be monitored for heart failure events, cardiovascular death, hospital visits related to heart failure, and other major cardiovascular outcomes. They will complete questionnaires about their heart failure symptoms and quality of life. Kidney function will also be assessed in some participants. Safety and effectiveness will be evaluated throughout the study period, which can last over three years, with regular visits for injections and assessments.

Age: 18Years +All GendersPhase 3
838 locations
R

Actively Recruiting

Researchers are evaluating whether adding zilovertamab vedotin to the standard treatment can help people with previously untreated diffuse large B-cell lymphoma DLBCL live longer without their cancer growing or spreading. This phase 3 randomized study compares the combination of zilovertamab vedotin with rituximab plus cyclophosphamide, doxorubicin, and prednisone R-CHP against the standard treatment of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone R-CHOP. Participants receive treatments in 21-day cycles for up to six cycles approximately four months. One group receives zilovertamab vedotin with rituximab or its biosimilar, cyclophosphamide, doxorubicin, and prednisone or similar steroids, while the other group receives rituximab or its biosimilar, cyclophosphamide, doxorubicin, vincristine, and prednisone or similar steroids. Both groups may receive up to two additional cycles of rituximab or its biosimilar as decided by the investigator. During the study, participants will have regular assessments including imaging scans and heart function tests to monitor their health and response to treatment. Researchers will measure how long participants live without disease progression, overall survival, response rates, and quality of life up to several years. Safety is monitored by tracking adverse events and treatment discontinuations. The study lasts several years, with primary outcome assessments up to about 50 months and overall survival monitored up to approximately 74 months.

Age: 18Years +All GendersPhase 3
285 locations
P

Actively Recruiting

Researchers are evaluating the effects of elecoglipron compared with a placebo in adults with chronic kidney disease CKD, including those with and without type 2 diabetes mellitus T2DM. This Phase III, randomized, double-blind, placebo-controlled study includes participants who are receiving standard care treatments for CKD, including the SGLT2 inhibitor dapagliflozin. The study aims to determine whether elecoglipron can reduce the risk of kidney function decline, end-stage kidney disease, and mortality. Participants will be randomly assigned to receive either elecoglipron tablets or matching placebo tablets once daily. The study is multicenter and involves parallel groups. The treatment period and evaluation are event-driven and may last up to 4.5 years. Both study groups will continue their background therapies for CKD alongside the study medication or placebo. During the study, participants will be monitored regularly to assess kidney function, cardiovascular events, and overall health outcomes, including mortality. Researchers will measure sustained declines in estimated glomerular filtration rate eGFR, occurrence of end-stage kidney disease, cardiovascular death, heart failure hospitalizations, and other related outcomes. The study includes safety monitoring throughout the trial, which is expected to last until October 2030, with participant involvement potentially extending up to 4.5 years.

Age: 18Years +All GendersPhase 3
715 locations
E

Actively Recruiting

Researchers are evaluating the clinical efficacy of combining physiological pacing with atrioventricular node ablation in patients who have Heart Failure with preserved Ejection Fraction HFpEF and well-controlled permanent atrial fibrillation. The study aims to determine whether this combination reduces mortality and hospitalizations for heart failure compared to optimal medical therapy. This trial focuses on the potential benefit of heart rate regularization to prevent the negative effects of right ventricular apical pacing. Participants are randomly assigned to either the intervention group receiving pacemaker implantation with atrioventricular node ablation or the control group receiving optimized pharmacological therapy aimed at controlling heart rate. The pacemaker device will be programmed in VVIR mode at a lower rate of 75 beats per minute. The intervention procedures will occur within one week after randomization, and the control group will receive optimized rate control therapy according to current guidelines. Participants will visit the clinic at 3 months, 12 months, and 24 months after randomization for checkups and tests. Researchers will monitor outcomes including time to all-cause mortality or hospitalization due to heart failure or intravenous diuretics over 24 months. Secondary outcomes include cardiovascular mortality, heart failure hospitalizations, changes in clinical scores and biomarkers, and adverse events related to pacemaker implantation and ablation procedures. The total study duration extends to the end of 2029.

Age: 18Years +All GendersPhase Not Applicable
17 locations
A

Actively Recruiting

Healthy Volunteer

Researchers are studying children aged 6 to 11 years to better understand motor difficulties linked to Autism Spectrum Disorder ASD. This study aims to capture detailed and standardized measurements of general motor skills, fine motor skills, and eye movement control, while also exploring how these motor challenges relate to cognitive and social difficulties in children with ASD. The study compares motor performance across three key domains and examines differences based on clinical assessments, age, IQ, and other factors. Participants undergo a series of behavioral tests that assess eye movements using an eye-tracking system, fine motor tasks like graphics and pointing, and gross motor skills through biomechanical analysis. Children also complete self and parent questionnaires related to their motor and social functioning. Data collection occurs during visits spaced around three months apart to evaluate motor skills and related cognitive and social measures. Throughout the study, childrens motor performance is measured using objective tasks and eye-tracking technology, along with assessments of IQ, social responsiveness, ADHD symptoms, and motor coordination disorders. Researchers monitor changes and scores over visits to identify patterns and correlations. Participation involves completing motor tests and questionnaires, with outcomes focused on success rates, errors, reaction times, and clinical scores. The total study duration includes at least two visits spaced by approximately three months for comprehensive assessment.

Age: 6Years - 11YearsAll GendersPhase Not Applicable
4 locations
S

Actively Recruiting

Researchers are investigating a cognitive stimulation program adapted for elderly patients with bipolar disorder to address cognitive impairments that commonly worsen after age 65. Bipolar disorder is a mood disorder that significantly affects cognitive functions such as attention, memory, and executive skills, which in turn impact quality of life and relapse risk. This study compares the adapted cognitive stimulation program to usual psychiatric care to evaluate its effects on residual cognitive symptoms. Participants in the study will either undergo cognitive stimulation sessions using Liliane Israls TRAIN YOUR MEMORY software or receive standard care involving psychiatric consultations and possible home nurse visits. The cognitive stimulation includes weekly sessions focusing on sensory stimulation, language and expression, attention, memory structuring, social communication, and temporal-spatial orientation. This program is designed to enhance memory mechanisms through pedagogical and psychotherapeutic methods. During the trial, participants will be assessed with various cognitive and functional tests at inclusion, 3 months, and 6 months to measure changes in executive function, memory, daily activities, and mood. Key outcomes include scores on the Frontal Assessment Battery and other neuropsychological tests. Researchers will monitor hospitalizations due to relapse and caregiver burden. The total participation duration is at least 6 months, with assessments conducted throughout this period to evaluate treatment effects and safety.

Age: 65Years +All GendersPhase Not Applicable
1 location
O

Actively Recruiting

Researchers are studying acute hidrosadenitis to better understand its different types or phenotypes. This is important because recognizing these subtypes can help tailor more suitable treatments and care. The study aims to define the natural history of the disease and identify environmental factors linked to its chronic form over an average period of three years. This is an observational study where no treatments or interventions are tested. Instead, patients diagnosed with acute hidrosadenitis are followed over time to observe their condition. The study collects detailed information about the clinical forms of the disease and tracks how it progresses in patients. Participants will be monitored for about three years during which researchers will record data about their disease severity, clinical characteristics, and environmental exposures. The main outcomes measured include the different clinical forms of hidrosadenitis and factors that may influence chronic disease development. There is no specific treatment given rather, the study observes patients to gather valuable information for future care approaches.

All AgesAll Genders
13 locations

1-10 of 53

1